Biotricity Earnings Call Signals Profitable Pivot Ahead

Biotricity ((BTCY)) has held its Q3 earnings call. Read on for the main highlights of the call.

Biotricity’s latest earnings call struck a cautiously upbeat tone, with management emphasizing sustained revenue growth, sharp gross margin expansion and a clear march toward profitability. Executives acknowledged the company’s small absolute scale, ongoing net losses and regulatory dependencies, but argued that recurring revenue strength, cash generation and network effects now outweigh the remaining risks.

Revenue Growth

Biotricity reported quarterly revenue of $4.0 million, a 10.2% increase from $3.6 million a year earlier, underscoring steady top-line momentum. Management framed this as evidence that its cardiac monitoring platform is gaining traction despite a still early-stage commercial footprint.

Strong Gross Profit and Margin Expansion

Gross profit climbed to $3.3 million, up 17.6% year over year, as gross margin expanded by 516 basis points to 81.5%. The company credited a growing base of recurring technology fees and efficiency gains from AI, cloud and monitoring cost reductions for the margin improvement.

Recurring Revenue Mix

Technology fees accounted for 91.2% of total revenue, highlighting deep penetration of Biotricity’s Technology-as-a-Service subscription model. Usage-based subscriptions are driving a more predictable revenue stream, though the heavy concentration also creates exposure if adoption or retention were to soften.

Profitability Momentum (EBITDA and Cash Flow)

Biotricity posted positive EBITDA of $280,000, or roughly $0.01 per share, marking its third straight quarter in the black on this metric. The company also recorded its sixth consecutive quarter of positive free cash flow, signaling that the model is beginning to self-fund growth.

Reduced Operating Costs

Operating expenses fell 4.2% year over year to $2.8 million from $2.93 million, reflecting tighter cost control. Selling, general and administrative expenses dropped 8.2%, or about $195,000, as management continues to reshape the sales force and streamline overhead.

Product and Commercial Traction

Biocore Pro, the company’s next-generation cardiac monitor with cellular connectivity, continues to gain commercial traction. Management cited multiple large-scale pilot programs in hospitals and clinics and expressed confidence that these deployments will translate into broader adoption among existing and new customers.

Digital Ecosystem and Clinical Reach

Biotricity’s digital health ecosystem is scaling rapidly, with app users surging from 4,500 to more than 44,000 over the last two years. Its provider network has grown to more than 2,500 clinicians supporting roughly 400,000 patients annually, bolstered by contracts with three major GPOs that provide access to over 90% of U.S. hospitals.

Regulatory and International Progress

The company is pursuing U.S. FDA clearance for an AI-powered clinical model it believes can further enhance margins and clinical impact. Internationally, Biotricity is building on existing approvals in markets including the U.S., Canada, Saudi Arabia and Argentina as it seeks broader regulatory clearances to support future distribution.

Net Loss Remains

Despite improving metrics, Biotricity still posted a net loss attributable to common stockholders of $1.1 million for the quarter, or $0.042 per share. That compares with a $1.3 million loss, or $0.054 per share, a year earlier, indicating progress but underscoring that the business has not yet reached bottom-line breakeven.

Modest Absolute Scale of Revenue

Management was clear that the company remains modest in scale, with quarterly revenue of just $4.0 million despite double-digit growth. This early-stage profile leaves results sensitive to adoption trends and the timing of large customer wins, particularly in hospital systems.

EBITDA and Profit Levels are Small

While the shift to positive EBITDA is a milestone, the absolute contribution of $280,000 remains limited relative to the company’s ambitions. Biotricity is still in the transition phase from proving its model to delivering durable, net-income profitability.

Dependence on Technology Fee Revenue

The heavy reliance on technology fees, at 91.2% of revenue, underscores both the strength of Biotricity’s subscription platform and its concentration risk. Any slowdown in new subscriptions or weakening retention could have an outsized impact on overall results.

R&D Spend Increased

Research and development expenses rose by $72,000 year over year as the company continues to invest in product enhancements and regulatory pathways. Management framed this spending as essential to sustaining innovation, particularly around AI tools and new monitoring capabilities.

Regulatory and Commercial Execution Risks

Management acknowledged that future growth depends on successfully securing FDA clearance for its AI model and expanding international approvals. They also highlighted the inherently long sales cycles with large hospitals and GPO-driven accounts, which could temper the pace of near-term revenue acceleration.

Forward-Looking Guidance and Expectations

Looking ahead, Biotricity guided to continued top-line growth and projected a transition to net-income profitability in calendar 2026. Executives expect further margin gains and operating leverage as user and provider networks expand, while upcoming regulatory clearances and international approvals are seen as catalysts for both revenue and profitability.

Biotricity’s earnings call painted a picture of a company exiting its proof-of-concept phase and edging toward scale, with recurring revenue, high margins and cash flow momentum as key pillars. Investors will now watch whether regulatory wins, broader hospital adoption and continued cost discipline can carry the company across the threshold into sustained profitability.